CA2380018A1 - Immunotherapy in hiv infected persons using vaccines after multi-drug treatment - Google Patents
Immunotherapy in hiv infected persons using vaccines after multi-drug treatment Download PDFInfo
- Publication number
- CA2380018A1 CA2380018A1 CA002380018A CA2380018A CA2380018A1 CA 2380018 A1 CA2380018 A1 CA 2380018A1 CA 002380018 A CA002380018 A CA 002380018A CA 2380018 A CA2380018 A CA 2380018A CA 2380018 A1 CA2380018 A1 CA 2380018A1
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- hiv
- viral
- cell
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14624099P | 1999-07-28 | 1999-07-28 | |
US60/146,240 | 1999-07-28 | ||
US17898900P | 2000-01-28 | 2000-01-28 | |
US60/178,989 | 2000-01-28 | ||
US20044500P | 2000-04-28 | 2000-04-28 | |
US60/200,445 | 2000-04-28 | ||
PCT/US2000/020641 WO2001008702A2 (en) | 1999-07-28 | 2000-07-27 | Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2380018A1 true CA2380018A1 (en) | 2001-02-08 |
Family
ID=27386369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002380018A Abandoned CA2380018A1 (en) | 1999-07-28 | 2000-07-27 | Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1198248A2 (ja) |
JP (1) | JP2003505516A (ja) |
AU (1) | AU779494B2 (ja) |
CA (1) | CA2380018A1 (ja) |
WO (1) | WO2001008702A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054701A1 (en) * | 2000-01-31 | 2001-08-02 | Aventis Pasteur, S.A. | Vaccination of hiv infected persons following highly active antiretroviral therapy |
BRPI0415533A (pt) * | 2003-10-24 | 2006-12-26 | Immunaid Pty Ltd | método de terapia |
WO2006010106A2 (en) * | 2004-07-09 | 2006-01-26 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Dna-based vaccination of retroviral-infected individuals undergoing treatment |
WO2008089144A2 (en) * | 2007-01-12 | 2008-07-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Improved dna vaccination protocols |
ES2548508T3 (es) | 2009-05-27 | 2015-10-19 | Biotempus Limited | Métodos de tratamiento de enfermedades |
US11013791B2 (en) | 2017-06-22 | 2021-05-25 | The Government Of The United States, As Represented By The Secretary Of The Army | NYVAC-based plasmodium malaria vaccine |
CN109300529B (zh) * | 2018-09-12 | 2021-09-21 | 阿呆科技(北京)有限公司 | 基于人工智能和虚拟现实/增强现实的毒瘾渴求靶向干预矫治系统 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0942747A1 (en) * | 1996-08-26 | 1999-09-22 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
-
2000
- 2000-07-27 WO PCT/US2000/020641 patent/WO2001008702A2/en active IP Right Grant
- 2000-07-27 CA CA002380018A patent/CA2380018A1/en not_active Abandoned
- 2000-07-27 AU AU66128/00A patent/AU779494B2/en not_active Ceased
- 2000-07-27 JP JP2001513432A patent/JP2003505516A/ja active Pending
- 2000-07-27 EP EP00953728A patent/EP1198248A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU779494B2 (en) | 2005-01-27 |
WO2001008702A3 (en) | 2001-08-30 |
JP2003505516A (ja) | 2003-02-12 |
AU6612800A (en) | 2001-02-19 |
EP1198248A2 (en) | 2002-04-24 |
WO2001008702A9 (en) | 2001-09-20 |
WO2001008702A2 (en) | 2001-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7771729B2 (en) | Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors | |
KR100571479B1 (ko) | Hiv에 대한 폴리엔브백신으로서 재조합 백시니아벡터의 혼합물 | |
US20140377306A1 (en) | Recombinant vaccine viruses expressing il-15 and methods of using the same | |
AU2001259291A1 (en) | Improved immunogenicity using a combination of DNA and vaccinia virus vector vaccines | |
JP2000506727A (ja) | 組換え生ネコ免疫不全ウイルスおよびプロウイルスdnaワクチン | |
Abaitua et al. | Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma | |
MYAGKIKH et al. | Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques | |
US20090169503A1 (en) | Dna-based vaccination of retroviral-infected individuals undergoing treatment | |
AU779494B2 (en) | Immunotherapy in HIV infected persons using vaccines after multi-drug treatment | |
US20050019752A1 (en) | Novel chimeric rev, tat, and nef antigens | |
KENT et al. | Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses | |
US20040034209A1 (en) | Vaccination of hiv infected persons following highly active antiretrovial therapy | |
WO2001054701A9 (en) | Vaccination of hiv infected persons following highly active antiretroviral therapy | |
US20060094006A1 (en) | Immunotherapy regimens in hiv-infected patients | |
US6723558B1 (en) | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses | |
Stratov et al. | Phenotypic and kinetic analysis of effective simian–human immunodeficiency virus-specific T cell responses in DNA-and fowlpox virus-vaccinated macaques | |
WO2004043490A1 (en) | Smallpox vaccine regimen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |